Certain statements made during this conference call constitute forward-looking statements. These statements include the capabilities and success of the company's business and any of its products, services or solutions. The words believe, forecast, project, intend, expect, plan, should, would, and similar expressions and all statements which are not historical facts are intended to identify forward-looking statements. These forward-looking statements involve and are subject to known and unknown risks, uncertainties and other factors, any of which could cause the company to not achieve some or all of its goals or the company's previously reported actual results, performance, financial or operating, including those expressed or implied by such forward-looking statements. More detailed information about the company and the risk factors that may affect the realization of forward-looking statements is set forth in the company's filings with the Securities and Exchange Commission, the SEC, copies of which may be obtained from the SEC's web site at www.sec.gov. The company assumes no and hereby disclaims any obligation to update the forward-looking statements made during this conference call. Joining us on the call today are David Phipps, Chief Executive Officer, Amanda Ferrio, Chief Financial Officer, and Birute Norkute, Vice President of Healthcare Operations. I'll now turn the meeting over to David Phipps for his opening remarks. Good morning and welcome to NextPlat's year-end 2025 results conference call. Thank you for joining us. On today's call, we will discuss our annual results and highlight the significant turnaround progress we have made in improving our operations during the latter half of 2025. Most importantly, we want to share with you what we see in early 2026, specifically as it relates to our growth and profitability goals. Let me start by addressing the reverse split we announced last week. While the reverse split is not something we wanted to do, it was required to maintain our listing on Nasdaq. While our board and management team understand investor negativity around reverse splits, as collectively the largest shareholders, we don't believe NextPlat is representative of the kinds of companies that need to do reverse splits. Those companies are typically poorly capitalized with weak businesses, significant sometimes toxic debt, and very diluted share counts. NextPlat, on the other hand, is well capitalized with nearly $14 million in cash, no debt and high insider ownership. As we have previously communicated and will discuss at length today, we now have a fundamentally improving business with growing margins and an expanding new business pipeline. Furthermore, we are now expanding our healthcare business from the single state of Florida to nationwide with the ability to support customers and patients in all 50 states. In looking at the business, as previously discussed in our various shareholder updates and press releases, we are starting to see the positive results of our business turnaround efforts. These are particularly clear when looking at the dramatic decreases in our cost structure, a direct result of our efforts to streamline the business and reduce overhead, all of which are contributing to over $2 million in annualized cost reductions. Something Amanda L. Ferrio, our Chief Financial Officer, will discuss in more detail shortly. We are especially proud of our progress on not only cutting costs, but our successful efforts to improve the profitability of our healthcare business, which represented about 73% of our revenue in 2025. Our efforts here were focused on new business development, targeting higher margin 340B covered entities and long-term care facilities, securing medication fulfillment contracts, re-engagement with former clients, and improving our customer service. These initiatives are now delivering the growth and early signs of margin improvement in the first quarter of 2026. Details of which Birute Norkute will comment on shortly. I will now briefly recap the developments in the fourth quarter, then Birute will discuss progress within our healthcare segment, and Amanda will review our financial results. Following their presentations, I will provide some concluding high-level remarks on our shorter-term objectives and the positive developments you should expect to see from the company in 2026. After that, we will then conclude the conference call by responding to questions that were submitted by our shareholders. Let me begin by stating that the end of 2025 marked a significant turning point for NextPlat as we largely completed much of the work we outlined in our refocusing and business improvement plans. As we have shared with you, these plans were designed to improve operations, reduce costs, and grow the business with the goal of driving profitability in 2026. I'm pleased to say that as early first quarter 2026 data indicates we have been successful across a number of key operational and financial metrics, most notably early margin improvement, which is expected to ultimately support meaningful reductions in operating losses by the latter half of 2026. While we cannot provide too much detail today, we intend to provide our investors and the market with an update on our first quarter 2026 performance shortly after completing our financial close. I'd like to now review our business and provide some additional insights which I believe will be helpful for investors in measuring our progress. In our Healthcare segment, we are pleased to report the following improvements in operations during the fourth quarter. To start, we prioritize our focus on supporting medical clinics participating in the U.S. government's 340B Drug Pricing Program, which we refer to these clinics as covered entities. We support these covered entities with prescription management and fulfillment services, helping them meet their contracted patient adherence requirements. Our ability to drive adherence is a key differentiator for us that sets us apart from our competitors and something that helps us drive brand awareness and generate leads with other participating covered entities. These efforts resulted in a strong 94% increase in 340B contract revenue for the fourth quarter of 2025 versus the third quarter of 2025. Secondly, the contributions from recently added medication fulfillment contracts have surpassed expectations as we fulfill 7,000+ prescriptions per month to their two facilities in Florida. The service fees we recognize from these fulfillments are driving significant bottom line profit improvements each month. Finally, because of our newly created nationwide fulfillment partnership with HealthWarehouse, we intend to quickly leverage our relationships with current and potential customers, offering our services and support their operations in all 50 states. This is a milestone for our healthcare operation, setting the stage for us to expand our business and compete on a national level by leveraging our solid foundation in Florida. It should be noted that in 2025, our healthcare segment generated nearly $40 million in sales, or approximately 73% of our consolidated revenue, all from the single state of Florida. As you can imagine, our expansion beyond Florida into 49 additional states through our partnership with HealthWarehouse provides us with a large new pathway to drive growth in our healthcare business. In our e-commerce segment, here are our most recent highlights. We continue to set new annual sales records driven by strong growth in Internet of Things hardware and recurring high margin airtime revenue, which also reached all-time highs. This performance is highlighted by the annual sales of over 5,000 Iridium and Globalstar devices, along with more than 12,000 satellite-enabled trackers and messengers, both setting new annual sales records. We continue to expand our global footprint and product portfolio, highlighted by the selection of GTC as the exclusive distributor for personal messaging and tracking products by a leading global satellite network operator to countries in the Nordic region. A new IoT and 5G product distribution agreement with Telit Cinterion. Additionally, we also received a significant contract supporting a NATO customer, adding to our growing involvement with U.K. government and defense customers. Finally, we just launched e-commerce sales in five countries in South America through Mercado Libre, the largest e-commerce platform in Latin America, which we expect to drive continued growth in this segment. At this point, I would like to now turn the call over to Birute for her update. Thank you, David. As David noted in his opening remarks, our fourth quarter financial results reflect continued positive trends in our healthcare segment, specifically in our higher margin, 340B and new contracted medication fulfillment services, which is helping offset continued softness in retail prescription volumes. This is one of the reasons why we have chosen to focus our efforts on the higher margin contracted services instead of traditional retail business in the near term. While this may impact top line revenue and prescription volumes in the first half of 2026, we believe the improved unit economics make this a prudent strategy. Importantly, we believe the trends we are seeing in 340B and fulfillment services are sustainable and expected to continue building through 2026. We are already seeing early positive improvements on margins in retail and long-term care reimbursements, in part from the Medicare Maximum Fair Price program, which we expect to further support margin growth as the year progresses. Let me highlight some of the key areas where we made notable progress. As previously discussed, we have dramatically streamlined our operations and greatly enhanced our customer service while reducing our employee headcount by more than 25%. We continue to see a strong and sustainable turnaround in our 340B business, supported by the targeted service improvements and customer engagement efforts we implemented in late 2025. We are proud of the fact that former clients have returned and continue bringing more of their business back to us. New covered entities have joined us and the valuable customer prescription volumes are once again growing. Three new 340B entities started in the fourth quarter of 2025. Two more became active on January 1st, 2026, and we have several more lined up to start in the coming quarters of 2026. The recruitment of dedicated long-term care sales personnel combined with the refreshed and more targeted sales strategy is expected to re-accelerate growth in our long-term care segment. We are focusing on higher value facility partnerships, improving conversion rates, and strengthening the referral pipelines, which should translate into increased census and revenue contribution in the second half of the year. We implemented purchasing and inventory optimization strategies that generated meaningful one-time savings while establishing tighter controls on inventory levels going forward. These improvements reduced excess stock, improved turns, and are expected to deliver a sustained positive impact on cash flow management. We continue to nurture our partnership with an integrated care model organization that combines telehealth, clinical management, and 340B infrastructure, enabling us to reach high needs populations, including patients requiring MOUD, HIV, and hepatitis C care and unlocking new growth opportunities. Lastly, we are very encouraged that our partnership with HealthWarehouse is now effective, which expands our operational capabilities, contract opportunities, and market access. This positions us to drive meaningful growth and significantly scale our fulfillment capabilities going forward. That concludes my remarks. Back to you, David. Thank you, Birute. At this point, I will turn the call over to Amanda to discuss our financial results for the year ended December 31, 2025. Thank you, David. Good morning, everyone. As David mentioned, the fourth quarter of 2025 marked an important inflection point for the company as the benefits of our cost optimization and strategic refocusing initiatives began to materialize in our financial performance. For the year ended December 31, 2025, we reported total revenue of approximately $54 million compared to approximately $66 million in 2024, representing an 18% decline. This decrease was primarily driven by lower contributions from our healthcare operations segment, reflecting reduced 340B and retail prescription volumes earlier in the year. However, it's important to emphasize that while revenue declined year-over-year, the underlying fundamentals of the business have strengthened meaningfully, and we are seeing encouraging signs of stabilization and improvement as we exit the year. Within our healthcare operations, we made significant progress in repositioning the business toward more sustainable and higher margin revenue streams. Full year healthcare operations revenue was approximately $40 million compared to approximately $52 million in 2024. In the fourth quarter, revenues of approximately $9 million were relatively stable when sequentially compared to $10 million in the third quarter, reflecting a transition period. Encouragingly, in Q4, we saw a 94% increase in 340B contract revenue and initial contributions from higher margin medication fulfillment services and early signs of retail prescription stabilization. This aligns with our broader strategy outlined in our Form 10-K to shift towards data-driven, contract-based and recurring healthcare services, which we believe will improve both margins and predictability over time. As we enter 2026, we expect continued growth in 340B contract revenue and fulfillment services, gradual improvement in prescription volumes, and a favorable impact on margin profile over time. Our e-commerce operations continue to deliver steady growth with revenue increasing to approximately $15 million, up 6% year-over-year. This growth was driven by strong demand for satellite connectivity and Internet of Things products, as well as expansion of recurring airtime and subscription-based services. We expect this segment to remain a stable growth engine supported by global e-commerce expansion, marketplace diversification, and continued demand for mission-critical connectivity solutions. As a result of these shifts in our revenue mix, while consolidated gross margin for the full year was approximately 20% compared to approximately 26% in 2024, the more important trend is sequential improvement, including progress late in the fourth quarter, driven by higher margin healthcare services and improved unit economics driven by the focus on revenue quality. While first quarter 2026 gross margins reflect the early stages of our transition, we expect margins to improve progressively throughout the year, with a more meaningful step-up beginning in the second quarter as higher margin revenue streams continue to scale. A major achievement in 2025 was the reset of our operating cost structure. Total operating expenses decreased by approximately 25% to $20 million, compared to approximately $26 million in the prior year, excluding a non-recurring impairment charge in the prior year of nearly $14 million. Salaries and wages decreased by approximately 20%, and professional fees decreased by approximately 49%. These reductions reflect a leaner and more efficient operating structure. We expect continued expense discipline and further reductions in operating losses as we move through 2026. We ended the year with a solid balance sheet, including nearly $14 million in cash, no meaningful debt, and approximately $15 million in working capital. Cash usage declined significantly compared to the third quarter, and we expect relatively stable cash levels in the first half of 2026. This provides us with flexibility to support operations, invest selectively in growth, and evaluate strategic opportunities. In summary, we have stabilized the business after a challenging first half, significantly reduced our cost structure, and maintained a strong balance sheet and liquidity. We are now beginning to see the benefits of our shift toward higher margin recurring revenue streams and remain focused on driving profitable growth and continued improvement in bottom line performance. I encourage you to review our financial statements and disclosures in our annual report on Form 10-K for additional details. That concl udes my remarks. Back to you, David. Thank you, Amanda. Before we turn to investor questions, I would like to quickly recap the results of our turnaround efforts while providing some insights into where we are going and what to expect in 2026. With the completion of the fourth quarter, our team believes we have made significant progress executing our turnaround plans for NextPlat, putting us on a clear path toward improved profitability in 2026 and beyond. Despite that, the evidence of our progress is somewhat obscured by one-time expenses included in our annual results. The positive impact of our largely completed company-wide effort to streamline the business and invest in its growth will become increasingly evident as we move through 2026. As such, you should expect to see an update here when we pre-announce first quarter 2026 guidance shortly after our financial closing. That said, we have implemented $2 million+ in annualized overhead, staff, and other operational cost reductions. Changes to product and service offerings in healthcare are now driving meaningful improvements in financial and operational metrics, highlighted by expectations of continued gross margin improvement in the first quarter of 2026, with more meaningful expansion expected as we move through 2026, improved cash flows, reduction in operational losses, and substantially reduced cash burn expected throughout 2026. We aren't just focused on cutting costs. We are focused on growing the business. Through our new relationship with HealthWarehouse, we are now able to expand our healthcare offerings nationally beyond Florida. We are now able to support multi-state contracted customers and have already begun discussions with our clients. With the added resources of HealthWarehouse, we can now support the creation of new revenue streams, including e-commerce and online healthcare offerings for providers, patients, and consumers, similar to e-commerce offerings in communications. We have made great strides in rebuilding NextPlat, and we believe we are well positioned for continued improvement. In 2026, our board and management team are committed to delivering bottom-line results for our shareholders and to reward all those who have supported the company. At this point, we can now conduct the Q&A portion of today's call. We have again asked investors and shareholders to submit their questions in advance, and we would like to thank all of you who did. Question number one. Do you believe that the reverse split was necessary? Couldn't the company buy back stock in an effort to achieve the $1 minimum bid requirement? Firstly, I should say that the buyback program expired in December, and we have been in a blackout period since then, so repurchasing shares haven't been an option for us. It should be noted that the buyback program was designed to support the stock price, not drive it up. In fact, there are significant restrictions and guidelines imposed by the SEC and Nasdaq, which limit the ability of a company to influence its share price through a buyback program. Secondly, as we indicated last quarter, we are being prudent with our cash as we see opportunities to invest in the growth of the business. That being said, it's the view of our board of directors and management that maintaining our listing on Nasdaq is a critical part of our growth and expansion plans. As such, given the current market environment, the reverse split was the most viable option for the company at this time. Given the improving fundamentals and unrealized potential of the business, I want to say that our ongoing investment community engagement efforts with both current shareholders and prospective shareholders and analysts remains unchanged. We remain committed to additional proactive outreach and to employing additional investor relations resources throughout 2026. Question number two. What are the current plans for the buyback? Reinstating the program is something we are considering and will certainly announce any details on this when appropriate. Question number three. Can you comment on the status of the ongoing lawsuits? Does the accrual mean a settlement is pending? We continue to work with counsel to resolve the final remaining legal matter as quickly as possible while protecting the long-term interest of our shareholders. Clearly, there are two paths here. The first being proceeding to trial and the second being reaching a settlement. The ultimate path taken will depend on the opinion of counsel and that of our insurance company, which is why we took a non-cash contingency charge for potential future litigation costs should it be necessary. That was the final question that we received from investors. Thank you all again for submitting them. Please remember that you can submit your questions at our investor relations email, which is investors@nextplat.com, or with our IR contact listed on our press releases, Michael Glickman at mike@mwgco.net. That concludes our earnings conference call. We look forward to continuing to share with you our progress in the weeks and months ahead. Have a nice rest of your day. Thank you. Ladies and gentlemen, this concludes your conference call for today. We thank you for participating and we ask that you please disconnect your lines.